Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder

Journal of Affective Disorders

Volumn 207, Issue , 2017, Pages 54-62

  Sussman, Matthew ^a   Yu, Jeffrey ^a   Kamat, Siddhesh A ^b   Hartry, Ann ^c   Legacy, Susan ^b   Duffy, Ruth ^b   Aigbogun, Myrlene Sanon ^b  

^a Boston Health Economics   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c LUNDBECK RESEARCH USA   (United States)

Author keywords

Adjunctive therapy; Atypical antipsychotics; Brexpiprazole; Cost effectiveness; Major depressive disorder; Remission

Indexed keywords

BREXPIPRAZOLE; FLUOXETINE; OLANZAPINE; PLACEBO; QUETIAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; THIOPHENE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; MAJOR DEPRESSION; PRIORITY JOURNAL; REMISSION; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; AKATHISIA; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; FATIGUE; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; PATIENT SELECTION; SOMNOLENCE; WEIGHT GAIN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG COSTS; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PATIENT SELECTION; QUETIAPINE FUMARATE; QUINOLONES; SEROTONIN AGENTS; THIOPHENES; WEIGHT GAIN; YOUNG ADULT;

EID: 84989189538     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.09.006     Document Type: Article

References (51)

1. American Psychiatric Association, Guidelines for the treatment of patients with major depressive disorder. Am. J. Psychiatry, 167, 2010, A34.
2. AnalySource Drug Pricing Resource, 2015. 〈https://www.analysource.com〉 (accessed 01.03.15.).
3. Bauer, M., Pretorius, H.W., Constant, E.L., et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J. Clin. Psychiatry 70 (2009), 540–549.
4. Benedict, A., Arellano, J., De Cock, E., et al. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J. Affect Disord. 120 (2010), 94–104.
5. Birnbaum, H.G., Ben-Hamadi, R., Paul, E., et al. Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. PharmacoEconomics 27 (2009), 507–517.
6. Cha, D.S., McIntyre, R.S., Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin. Pharm., 13, 2012 1587–98.
7. Citrome, L., Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad. Med. 122 (2010), 39–48.
8. Connolly, K.R., Thase, M.E., If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 1 (2011), 43–64.
9. Cuffel, B.J., Azocar, F., Tomlin, M., et al. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J. Clin. Psychiatry 64 (2003), 397–402.
10. Edwards, S.J., Hamilton, V., Nherera, L., et al. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol. Assess. 17 (2013), 1–190.
11. El-Khalili, N., Joyce, M., Atkinson, S., et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicenter, randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 13 (2010), 917–932.
12. Fava, M., Rush, A.J., Wisniewski, S.R., et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a START⋆D report. Am. J. Psychiatry 163 (2006), 1161–1172.
13. Ferrari, A.J., Charlson, F.J., Norman, R.E., et al. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease study 2010. PLoS Med., 10, 2013, e1001547.
14. Gao, K., Kemp, D.E., Feln, E., et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J. Clin. Psychol. 72:8 (2011), 1063–1071.
15. Gaynes, B.N., Jackson, W.C., Rorie, K.D., Major depressive disorder in the primary care setting: Strategies to achieve remission and recovery. J. FamPrac 64 (2015), S1–S15.
16. Gelenberg AJ, Freeman MP, Markowitz JC, et al., 2010. American Psychiatric Association: practice guideline for the treatment of patients with major depressive disorder, third ed. Arlington, Virginia.
17. Gilchrist, G., Gunn, J., Observational studies of depression in primary care: what do we know?. BMC Fam. Pract., 8, 2007, 28.
18. Greenberg, P.E., Fournier, A.-A., Sisitsky, T., et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry 76 (2015), 155–162.
19. Han, C., Yeh, T.L., Kato, M., et al. Management of chronic depressive patients with residual symptoms. CNS Drugs 27 (2013), S53–S57.
20. IHS Global Pricing and Reimbursement. 〈https://www.ihs.com/products/pricing-and-reimbursement-market-analysis.html〉. (accessed 17.03.15.).
21. Ivanova, J.I., Birnbaum, H.G., Kidolezi, Y., et al. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr. Med. Res. Opin. 26 (2010), 2475–2484.
22. Kessler, R.C., The costs of depression. Psychiatr. Clin. North Am. 35 (2012), 1–14.
23. Kessler, R.C., Berglund, P., Demler, O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003), 3095–3105.
24. Kessler, R.C., Berglund, P., Demler, O., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005), 593–602.
25. Knoth, R.L., Bolge, S.C., Kim, E., et al. Effect of inadequate response to treatment in patients with depression. Am. J. Manag. Care 16 (2010), e188–e196.
26. Legacy, S., McMorrow, D., Duffy, R.A., et al., 2015. Delay in use of adjunct atypical antipsychotic treatment for major depressive disorder is associated with higher physician office visits and costs. In: Proceedings of the Abstract presented at the American Psychiatric Association 168th Annual Meeting; May 16–20, 2015; Toronto, Canada.
27. Lenox-Smith, A., Greenstreet, L., Burslem, K., Knight, C., Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clin. Drug Investig. 29 (2009), 173–184.
28. Malone, D.C., A budget-impact and cost-effectiveness model for second-line treatment of major depression. J. Manag. Care 13 (2007), S8–S18.
29. Mauskopf, J.A., Simon, G.E., Kalsekar, A., et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress. Anxiety 26 (2009), 83–97.
30. Nelson, J.C., Papakostas, G.I., Atypical antipsychotic augmentation in major depressive disorder: a metaanalysis of placebo-controlled randomized trials. Am. J. Psychiatry 166 (2009), 980–991.
31. Nierenberg, A.A., DeCecco, L.M., Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J. Clin. Psychiatry 62 (2001), S5–S9.
32. Nierenberg, A.A., Petersen, T.J., Alpert, J.E., Prevention of relapse and recurrence in depression: the role of longterm pharmacotherapy and psychotherapy. J. Clin. Psychiatry 64 (2003), S13–S17.
33. Nordstrom, G., Despiegel, N., Marteau, F., et al. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J. Med. Econ. 13 (2010), 516–526.
34. Otsuka Pharmaceutical Co., Ltd. Rexulti (brexpiprazole), 2015. 〈https://www.rexulti.com/us/mdd/important-safety-information/?ceid=9086&utm_source=google&utm_medium=cpc&utm_campaign=brandedmdd&utm_term=brexpiprazole&utm_content=textad〉. (accessed 28.12.15.).
35. Papakostas, G.I., Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J. Clin. Psychiatry 70 (2009), S16–S25.
36. Patkar, A.A., Pae, C.U., Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 27 (2013), S29–S37.
37. Red Book. 〈http://sites.truvenhealth.com/redbook/index.html〉 (accessed 01.03.15.).
38. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR⋆D report. Am. J. Psychiatry 163 (2006), 1905–1917.
39. Russell, J.M., Hawkins, K., Ozminkowski, R.J., et al. The cost consequences of treatment-resistant depression. J. Clin. Psychiatry 65 (2004), 341–347.
40. Saylan, M., Treur, M.J., Postema, R., et al. Cost-effectiveness analysis of aripiprazole augmentation treatment of patients with major depressive disorder compared to olanzapine and quetiapine augmentation in Turkey: a microsimulation approach. Value Health Reg. Issues 2 (2013), 171–180.
41. Shelton, R.C., Tollefson, G.D., Tohen, M., et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158 (2001), 131–134.
42. Shelton, R.C., Douglas, J.W., Corya, S.A., et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled studyof SSRI and nortriptyline resistance. J. Clin. Psychiatry 66 (2005), 1289–1297.
43. Simon, G.E., Khandker, R.K., Ichikawa, L., Operskalski, B.H., Recovery from depression helps predict lower health services costs. J. Clin. Psychiatry 67 (2006), 1226–1231.
44. Sobocki, P., Ekman, M., Agren, H., et al. Resource use and costs associated with patients treated for depression in primary care. Eur. J. Health Econ. 8 (2007), 67–76.
45. Spielmans, G.I., Berman, M.I., Linardators, E., et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med., 10, 2013, e1001403.
46. Taneja, C., Papakostas, G.I., Jing, Y., et al. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann. Pharm. 46 (2012), 642–649.
47. Thase, M.E., Corya, S.A., Osuntokun, O., et al. Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry 68 (2007), 224–236.
48. Thase, M.E., Youakim, J.M., Skuban, A., et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J. Clin. Psychiatry 76 (2015), 1224–1231.
49. Thase, M.E., Youakim, J.M., Skuban, A., et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J. Clin. Psychiatry 76 (2015), 1232–1240.
50. Trivedi, M.H., Wan, G.J., Mallick, R., et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J. Clin. Psychopharm. 24 (2004), 497–506.
51. Zimovetz, E.A., Wolowacz, S.E., Classi, P.M., et al. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost. Eff. Resour. Alloc., 10, 2012, 1.